Publications by authors named "Raymond Despax"
Article Synopsis
- - The study aimed to evaluate the effectiveness and safety of combining eribulin with bevacizumab as a first-line treatment for HER2-negative metastatic breast cancer, comparing it to previous regimens like paclitaxel.
- - In a clinical trial involving 61 women, the combination treatment resulted in a 32% non-progression rate at one year and a median progression-free survival of 8.3 months, indicating promising results.
- - Adverse effects were reported, with hypertension (39%) and neutropenia (26%) being the most common serious side effects, but overall, the treatment was considered to have an acceptable safety profile with low rates of severe neuropathy.
Background: Expression IV survey evaluated the patients' expectations to a maintenance therapy.
Methods: From January 2015 to March 2016, 401 French patients, in first line or recurrent disease, answered a 24-items anonymous questionnaire. The results were specifically analyzed according to the demographic characteristics and treatment lines.